Spark Therapeutics, Inc. (NASDAQ:ONCE)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a report issued on Friday, MarketBeat Ratings reports. They presently have a $101.00 price objective on the biotechnology company’s stock, up from their prior price objective of $92.00. Stifel Nicolaus’ price target points to a potential upside of 19.91% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. ValuEngine raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. BidaskClub raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. William Blair assumed coverage on shares of Spark Therapeutics in a report on Wednesday, June 28th. They issued an “outperform” rating on the stock. Jefferies Group LLC assumed coverage on shares of Spark Therapeutics in a report on Monday, July 10th. They issued a “buy” rating and a $85.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $90.75.

Spark Therapeutics (ONCE) traded down 2.29% on Friday, hitting $84.23. 1,935,993 shares of the stock traded hands. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $91.75. The stock has a 50-day moving average price of $85.85 and a 200 day moving average price of $85.85. The company’s market cap is $2.63 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. Spark Therapeutics’s revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.04) earnings per share. On average, analysts anticipate that Spark Therapeutics will post ($7.64) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Spark Therapeutics, Inc. (ONCE) Stock Rating Reaffirmed by Stifel Nicolaus” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/13/spark-therapeutics-inc-once-price-target-raised-to-101-00-at-stifel-nicolaus.html.

In other news, Director Anand Mehra sold 211,858 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $70.15, for a total transaction of $14,861,838.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Daniel Faga sold 1,500 shares of the company’s stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the sale, the insider now owns 1,500 shares in the company, valued at $127,500. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,333,195 shares of company stock worth $109,070,506. Company insiders own 7.30% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors increased its position in shares of Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after purchasing an additional 414 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Spark Therapeutics by 10.9% in the first quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock worth $5,923,000 after purchasing an additional 10,916 shares during the last quarter. American International Group Inc. increased its position in shares of Spark Therapeutics by 17.4% in the first quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock worth $618,000 after purchasing an additional 1,714 shares during the last quarter. Cornerstone Capital Management Holdings LLC. bought a new position in shares of Spark Therapeutics in the first quarter worth approximately $572,000. Finally, Principal Financial Group Inc. increased its position in shares of Spark Therapeutics by 0.3% in the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after purchasing an additional 122 shares during the last quarter. Hedge funds and other institutional investors own 77.84% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.